Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, Andrew Kuykendall, Sebastian Grosicki et al.|The Lancet|2023Cited by 181
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studiesVikas Gupta, Srđan Verstovšek, Claire Harrison et al.|Haematologica|2016Cited by 85
Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed<i>/</i>Refractory MyelofibrosisJohn Mascarenhas, Maciej Kaźmierczak, Viola Maria Popov et al.|Blood|2024Cited by 15